Classification of anticancer drugs -: a new system based on therapeutic targets

被引:125
作者
Espinosa, E [1 ]
Zamora, P [1 ]
Feliu, J [1 ]
Barón, MG [1 ]
机构
[1] Hosp La Paz, Med Oncol Serv, Madrid 28046, Spain
关键词
antineoplastic drugs chemotherapy; classification; monoclonal antibodies; new drugs; small molecules;
D O I
10.1016/S0305-7372(03)00116-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The arrival of a great number of new antineoplastic agents has made it necessary to reclassify all of them. Anticancer drugs may act at different levels: cancer cells, endothelium, extracellular matrix, the immune system or host cells. The tumour cell can be targeted at the DNA, RNA or protein level. Most classical chemotherapeutic agents interact with tumour DNA, whereas monoclonal antibodies and small molecules are directed against proteins. The endothelium and extracellular matrix may be affected also by specific antibodies and small molecules. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:515 / 523
页数:9
相关论文
共 96 条
[41]  
Hoekman K, 2001, CANCER J, V7, pS134
[42]   Matrix metalloproteinase inhibitors: Current developments and future perspectives [J].
Hoekstra, R ;
Eskens, FALM ;
Verweij, J .
ONCOLOGIST, 2001, 6 (05) :415-427
[43]   Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336 [J].
Hoover, RR ;
Mahon, FX ;
Melo, JV ;
Daley, GQ .
BLOOD, 2002, 100 (03) :1068-1071
[44]   BAY 43-9006: Early clinical data in patients with advanced solid malignancies [J].
Hotte, SJ ;
Hirte, HW .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (25) :2249-2253
[45]   DNA and its associated processes as targets for cancer therapy [J].
Hurley, LH .
NATURE REVIEWS CANCER, 2002, 2 (03) :188-200
[46]   Antisense therapy for cancer - the time of truth [J].
Jansen, B ;
Zangemeister-Wittke, U .
LANCET ONCOLOGY, 2002, 3 (11) :672-683
[47]   Management of malignant gastrointestinal stromal tumours [J].
Joensuu, H ;
Fletcher, C ;
Dimitrijevic, S ;
Silberman, S ;
Roberts, P ;
Demetri, G .
LANCET ONCOLOGY, 2002, 3 (11) :655-664
[48]   Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities [J].
Jonasch, E ;
Haluska, FG .
ONCOLOGIST, 2001, 6 (01) :34-55
[49]   Current status of clinical trials of farnesyltransferase inhibitors [J].
Karp, JE ;
Kaufmann, SH ;
Adjei, AA ;
Lancet, JE ;
Wright, JJ ;
End, DW .
CURRENT OPINION IN ONCOLOGY, 2001, 13 (06) :470-476
[50]   Effects of interferon-γ on secretion of vascular endothelial growth factor by endometrial stromal cells [J].
Kawano, Y ;
Matsui, N ;
Kamihigashi, S ;
Narahara, H ;
Miyakawa, I .
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2000, 43 (01) :47-52